Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 20

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 20
---
 either to augment our own sales force and distribution systems or in lieu of its own sales force and
distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully
commercialize our clinical assets. If we are unable to successfully commercialize our clinical assets, either on our own or through collaborations
with one or more third parties, our business, financial condition, operating results, and prospects would suffer.

Our
failure to successfully in-license, acquire, develop, and market additional clinical assets or approved products would impair our ability
to grow our business.

We
intend to in-license, acquire, develop, and market additional products and clinical assets and we may in-license or acquire commercial-stage
products or engage in other strategic transactions. Because our internal research and development capabilities are limited, we may be
dependent upon pharmaceutical companies, academic scientists, and other researchers to sell or license products or technology to us.
The success of this strategy depends partly upon our ability to identify and select promising pharmaceutical clinical assets and products,
negotiate licensing or acquisition agreements with their current owners, and finance these arrangements.

41

The
process of proposing, negotiating, and implementing a license or acquisition of a clinical asset or approved product is lengthy and complex.
Other companies, including some with substantially greater financial, marketing, sales, and other resources, may compete with us for
the license or acquisition of clinical assets and approved products. We have limited resources to identify and execute the acquisition
or in-licensing of third-party products, businesses, and technologies and integrate them into our current infrastructure. Moreover, we
may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated
benefits of such efforts. We may not be able to acquire the rights to additional clinical assets on terms that we find acceptable, or
at all. 

Further,
any clinical asset that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical
testing and approval by the FDA and applicable foreign regulatory authorities. All clinical assets are prone to risks of failure typical
of pharmaceutical product development, including the possibility that a clinical asset will not be shown to be sufficiently safe and
effective for approval by regulatory authorities. In addition, we cannot provide assurance that any approved products that we acquire
will be manufactured or sold profitably or achieve market acceptance.

Additional
potential transactions that we may consider include a variety of different business arrangements, including spin-offs